|PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 05/06/2019|
As previously announced, on February 18, 2019, Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) and Pernix’s wholly-owned subsidiaries filed voluntary petitions for relief (the “Chapter 11 Cases”) under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware.
On April 30, 2018, the Company and certain of its subsidiaries (together, the “Sellers”) completed the previously announced sale of substantially all of its assets (the “Asset Sale”) to Currax Holdings LLC (f/k/a Phoenix Top Holdings LLC, an entity formed by affiliates of Highbridge Capital Management (in such capacity, the “Purchaser”)), pursuant to the Amended and Restated Asset Purchase Agreement, dated as of April 15, 2019 (as amended, the “A&R Purchase Agreement”) between the Sellers and the Purchaser.
The foregoing description of the A&R Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the A&R Purchase Agreement, filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on April 19, 2019.
Additional Information regarding the Chapter 11 Case
Additional information is available on Pernix’s website at www.pernixtx.com. In addition, court filings and other documents related to the Chapter 11 Cases are available on a separate website administered by Pernix’s claims and noticing agent, Prime Clerk, at https://cases.primeclerk.com/pernix.